Virtu Financial LLC Has $662,000 Stake in Iqvia Holdings Inc (IQV)

Virtu Financial LLC lifted its holdings in shares of Iqvia Holdings Inc (NYSE:IQV) by 31.1% in the third quarter, according to its most recent filing with the SEC. The firm owned 5,099 shares of the medical research company’s stock after acquiring an additional 1,209 shares during the period. Virtu Financial LLC’s holdings in Iqvia were worth $662,000 as of its most recent filing with the SEC.

Several other large investors have also added to or reduced their stakes in the company. Nomura Asset Management Co. Ltd. lifted its holdings in shares of Iqvia by 1.9% during the 3rd quarter. Nomura Asset Management Co. Ltd. now owns 25,186 shares of the medical research company’s stock worth $3,268,000 after acquiring an additional 461 shares during the period. IFM Investors Pty Ltd lifted its holdings in shares of Iqvia by 5.4% during the 3rd quarter. IFM Investors Pty Ltd now owns 9,290 shares of the medical research company’s stock worth $1,205,000 after acquiring an additional 478 shares during the period. State Treasurer State of Michigan lifted its holdings in shares of Iqvia by 1.0% during the 3rd quarter. State Treasurer State of Michigan now owns 48,300 shares of the medical research company’s stock worth $6,266,000 after acquiring an additional 500 shares during the period. Independent Advisor Alliance lifted its holdings in shares of Iqvia by 4.9% during the 3rd quarter. Independent Advisor Alliance now owns 11,240 shares of the medical research company’s stock worth $1,455,000 after acquiring an additional 525 shares during the period. Finally, Gateway Investment Advisers LLC lifted its holdings in shares of Iqvia by 9.1% during the 3rd quarter. Gateway Investment Advisers LLC now owns 6,770 shares of the medical research company’s stock worth $878,000 after acquiring an additional 563 shares during the period. 89.33% of the stock is owned by institutional investors.

In other news, Director Group Holdings (Sbs) Advis Tpg sold 3,573,545 shares of Iqvia stock in a transaction that occurred on Tuesday, December 4th. The shares were sold at an average price of $123.72, for a total transaction of $442,118,987.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Canada Pension Plan Investment sold 3,164,388 shares of Iqvia stock in a transaction that occurred on Tuesday, December 4th. The stock was sold at an average price of $123.72, for a total transaction of $391,498,083.36. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 7,117,903 shares of company stock valued at $881,082,166. Insiders own 6.00% of the company’s stock.

Shares of NYSE IQV opened at $121.85 on Friday. Iqvia Holdings Inc has a 1-year low of $91.57 and a 1-year high of $135.48. The stock has a market capitalization of $24.64 billion, a price-to-earnings ratio of 27.95, a P/E/G ratio of 1.77 and a beta of 0.81. The company has a quick ratio of 1.09, a current ratio of 1.09 and a debt-to-equity ratio of 1.41.

Iqvia (NYSE:IQV) last announced its earnings results on Monday, October 22nd. The medical research company reported $1.42 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.39 by $0.03. Iqvia had a net margin of 12.29% and a return on equity of 13.69%. The company had revenue of $2.59 billion during the quarter, compared to the consensus estimate of $2.58 billion. Iqvia’s quarterly revenue was up 5.2% on a year-over-year basis. On average, equities research analysts anticipate that Iqvia Holdings Inc will post 5.13 earnings per share for the current year.

A number of research firms have recently commented on IQV. Morgan Stanley raised their price objective on shares of Iqvia from $130.00 to $145.00 and gave the stock an “overweight” rating in a report on Monday. Zacks Investment Research downgraded shares of Iqvia from a “buy” rating to a “hold” rating in a report on Thursday, October 25th. Royal Bank of Canada lifted their price target on shares of Iqvia to $137.00 and gave the company an “outperform” rating in a report on Tuesday, October 23rd. Piper Jaffray Companies lifted their price target on shares of Iqvia to $131.00 and gave the company a “neutral” rating in a report on Tuesday, October 23rd. Finally, Barclays lifted their price target on shares of Iqvia from $130.00 to $140.00 and gave the company an “overweight” rating in a report on Tuesday, October 23rd. Five investment analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $134.41.

COPYRIGHT VIOLATION WARNING: This article was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international trademark and copyright law. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/12/07/virtu-financial-llc-has-662000-stake-in-iqvia-holdings-inc-iqv.html.

Iqvia Company Profile

IQVIA Holdings Inc provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.

Featured Article: What is a bull market?

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iqvia Holdings Inc (NYSE:IQV).

Institutional Ownership by Quarter for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply